Delisting riskPopularity #5,057
Solésence (SLSN)
Develops and manufactures mineral-UV skin-health formulations for brand partners.
$0.8060
After hours−0.02 (−2.30%)
At close$0.8250(+1.34%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 10 | 13 | 17 | 13 | 15 | 20 | 15 | 12 | 13 | 15 |
| Cost of revenue | 8 | 6 | 9 | 11 | 10 | 11 | 14 | 11 | 9 | 10 | 11 |
| Gross profit | 0 | 4 | 4 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 5 |
| 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 3 | 4 | 5 | |
| Research & development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Selling, general & administrative | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 4 |
| Operating income | −2 | 1 | 1 | 3 | 0 | 0 | 2 | −1 | 0 | −1 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 |
| Income before tax | −2 | 1 | 1 | 3 | 0 | 0 | 3 | −1 | 0 | −1 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −2 | 1 | 1 | 3 | −1 | 0 | 3 | −1 | 0 | −1 | 0 |
| Net income | −2 | 1 | 1 | 3 | −1 | 0 | 3 | −1 | 0 | −1 | 0 |
| EPS, basic | −$0.04 | $0.02 | $0.02 | $0.04 | −$0.01 | $0.00 | $0.04 | −$0.02 | $0.00 | −$0.01 | −$0.00 |
| EPS, diluted | −$0.04 | $0.01 | $0.01 | $0.04 | −$0.01 | $0.00 | $0.04 | −$0.02 | $0.00 | −$0.01 | −$0.00 |
| Weighted average shares, basic | 50 | 53 | 57 | 70 | 70 | 70 | 70 | 71 | 71 | 71 | 71 |
| Weighted average shares, diluted | 50 | 69 | 59 | 72 | 70 | 73 | 72 | 71 | 73 | 71 | 71 |
| EBITDA | −2 | 1 | 1 | 3 | 0 | 0 | 3 | −1 | 0 | 0 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −2 | 1 | 1 | 3 | 0 | 0 | 3 | −1 | 0 | −1 | 0 |